Almac Group turnover surpasses £500m for first time
The global contract pharmaceutical development and manufacturing organisation reports a 19% rise in its revenue
Almac Group, a global contract pharmaceutical development and manufacturing organisation, has reported a 19% rise in revenue to reach £531 million. The global company has also reported an increase in pre-tax profits, up from £27m in 2016 to more than £33m.
Globally, employee figures increased by more than 10% to 4407. Of this total 2920 staff are employed at Craigavon, representing an increase of also 10% or 270 staff on the previous year.
The figures were recorded in Almac’s annual report with its results for the year ending 30 September 2017.
2016 pre-tax profit was recorded at £27m. This year’s figure of £33m benefited from upfront and other payments relating to the out-licensing of oncology products that had been developed in house by the group and also contributed to the profit before tax figure for the year.
The company continued to invest in expansion projects in 2017 with the building of additional lab and office facilities and the ongoing construction of one of the largest pharmaceutical cold store facilities in Europe at its Global HQ campus in Craigavon.
Alan Armstrong, Group CEO, commented: “2017 was a strong year for Almac with turnover more than £531m and profits surpassing £33m. During the year we made significant investment for the long term benefit of the group including global expansion into key strategic territories. The financial benefit of these investments may not be realised immediately, however they will ensure steady and continued growth of the group into the future.”
“All our profits are reinvested into the business enabling us to offer best-in-class services and products to our clients and continue to be a leader in the life sciences sector.”
